New agents and regimens for diffuse large B cell lymphoma

1.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRef

2.

Morrison VA, Bell JA, Hamilton L, Ogbonnaya A, Shih H-C, Hennenfent K, et al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol. 2018;14(25):2627–42. https://doi.org/10.2217/fon-2018-0267.CrossRefPubMed

3.

Miao Y, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16(10):634–52. https://doi.org/10.1038/s41571-019-0225-1.CrossRefPubMed

4.

Offner F, Samoilova O, Osmanov E, Eom HS, Topp MS, Raposo J, et al. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. Blood. 2015;126(16):1893–901. https://doi.org/10.1182/blood-2015-03-632430.CrossRefPubMedPubMedCentral

5.

Nowakowski GS, Chiappella A, Witzig TE, Spina M, Gascoyne RD, Zhang L, et al. ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncol. 2016;12(13):1553–63. https://doi.org/10.2217/fon-2016-0130.CrossRefPubMedPubMedCentral

6.

Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–95. https://doi.org/10.1200/JCO.18.02403.CrossRefPubMedPubMedCentral

7.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–9. https://doi.org/10.1200/JCO.18.01994.CrossRefPubMedPubMedCentral

8.

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5. https://doi.org/10.1182/blood-2010-03-276246.CrossRefPubMedPubMedCentral

9.

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–8. https://doi.org/10.1182/blood-2017-03-769620.CrossRefPubMedPubMedCentral

10.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44. https://doi.org/10.1056/NEJMoa1707447.CrossRefPubMedPubMedCentral

11.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–54. https://doi.org/10.1056/NEJMoa1708566.CrossRefPubMedPubMedCentral

12.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. https://doi.org/10.1056/NEJMoa1804980.CrossRefPubMed

13.

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. https://doi.org/10.1016/S1470-2045(18)30864-7.CrossRefPubMed

14.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, et al. A Comparison of 2-year outcomes in ZUMA-1 (axicabtagene ciloleucel [Axi-Cel]) and SCHOLAR-1 in patients (Pts) with refractory large B cell lymphoma (LBCL). Biol Blood Marrow Transplant. 2020;26(3):S232. https://doi.org/10.1016/j.bbmt.2019.12.474.CrossRef

15.

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobsen ED, et al. Long-term follow-up ZUMA-1: a pivotal trial of axicabtagene ciloleucel (Axi-Cel; KTE-C19) in patients with refractory aggressive non-hodgkin lymphoma (NHL). Blood. 2017;130(Suppl 1):578.

16.

Bukhari A, Chaer FE, Koka R, Singh Z, Hutnick E, Ruehle K, et al. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. Am J Hematol. 2019;94(10):E273–5. https://doi.org/10.1002/ajh.25591.CrossRefPubMed

17.

Hossain N, Sahaf B, Abramian M, Spiegel JY, Kong K, Kim S, et al. Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies. Blood. 2018;132(Suppl. 1):490. https://doi.org/10.1182/blood-2018-99-110142.CrossRef

18.

Sang W, Shi M, Yang J, Cao J, Xu L, Yan D, et al. Combination of anti-CD19 and anti-CD20 chimeric antigen receptor T cells for relapsed and refractory diffuse larger B cell lymphoma: an open-label, single-arm, Phase I/II Trial. Blood. 2019;134(Supplement_1):1590. https://doi.org/10.1182/blood-2019-127640.CrossRef

19.

Suarez ER, de Chang K, Sun J, Sui J, Freeman GJ, Signoretti S, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7(23):34341–55. https://doi.org/10.18632/oncotarget.9114.CrossRefPubMedPubMedCentral

20.

Chong EA, Melenhorst JJ, Svoboda J, Dwivedy Nasta S, Landsburg DJ, Mato AR, et al. Phase I/II study of pembrolizumab for progressive diffuse large B cell lymphoma after anti-CD19 directed chimeric antigen receptor modified T cell therapy. Blood. 2017;130(Supplement 1):4121. https://doi.org/10.1182/blood.V130.Suppl_1.4121.4121.CrossRef

21.

Ardeshna KM, Marzolini MAV, Norman J, Al-Hajj M, Thomas S, Faulkner J, et al. Phase 1/2 study of AUTO3 the first bicistronic chimeric antigen receptor (CAR) targeting CD19 and CD22 followed by an anti-PD1 in patients with relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL): results of cohort 1 and 2 of the Alexander study. Blood. 2019;134(Supplement):246. https://doi.org/10.1182/blood-2019-122724.CrossRef

22.

Jacobson CA, Locke FL, Miklos DB, Herrera AF, Westin JR, Lee J, et al. End of phase 1 results from zuma-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma. Blood. 2018;132(Supplement 1):4192. https://doi.org/10.1182/blood-2018-99-111523.CrossRef

23.

Benjamin R, Graham C, Yallop D, Jozwik A, Ciocarlie O, Jain N, et al. Preliminary data on safety, cellular kinetics and antileukemic activity of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a pool of adult and pediatric patients with high-risk CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia. Blood. 2018;132(Suppl. 1):896. https://doi.org/10.1182/blood-2018-99-111356.CrossRef

24.

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545–53. https://doi.org/10.1056/NEJMoa1910607.CrossRefPubMedPubMedCentral

25.

Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. https://doi.org/10.1038/mto.2016.11.CrossRefPubMedPubMedCentral

26.

Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci USA. 2016;113(4):E459–68. https://doi.org/10.1073/pnas.1524155113.CrossRefPubMed

27.

Katz DA, Chu MP, David KA, Thieblemont C, Morley NJ, Khan SS, et al. Open-label, phase 2 study of blinatumomab after first-line rituximab-chemotherapy in adults with newly diagnosed, high-risk diffuse large B-cell lymphoma. Blood. 2019;134(Supplement_1):4077. https://doi.org/10.1182/blood-2019-121708.CrossRef

28.

Coyle L, Morley NJ, Rambaldi A, Mason KD, Verhoef G, Furness CL, et al. Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2020. https://doi.org/10.1080/10428194.2020.1759055.CrossRefPubMed

29.

Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, et al. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer. 2020;126(14):3192–201. https://doi.org/10.1002/cncr.32909.CrossRefPubMed

30.

Morschhauser F, Carlo-Stella C, Offner F, Salles GA, Hutchings M, Iacoboni G, et al. Dual CD20-targeted therapy with concurrent CD20-TCB and obinutuzumab shows highly promising clinical activity and manageable safety in relapsed or refractory B-cell non-Hodgkin lymphoma: preliminary results from a phase Ib trial. Blood. 2019;134(Supplement_1):1584. https://doi.org/10.1182/blood-2019-123949.CrossRef

31.

Budde LE, Sehn LH, Assouline S, Flinn IW, Isufi I, Yoon S-S, et al. Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. Blood. 2018;132(Supplement 1):399. https://doi.org/10.1182/blood-2018-99-118344.CrossRef

32.

Bannerji R, Allan JN, Arnason JE, Brown JR, Advani RH, Barnes JA, et al. Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Blood. 2019;134(Supplement_1):762. https://doi.org/10.1182/blood-2019-122451.CrossRef

33.

Garciaz S, Coso D, Schiano de Colella J-M, Bouabdallah R. Lenalidomide for the treatment of B-cell lymphoma. Expert Opin Investig Drugs. 2016;25(9):1103–16. https://doi.org/10.1080/13543784.2016.1208170.CrossRefPubMed

34.

Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, et al. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J. 2018;8(11):108.CrossRef

35.

Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas R-O, Fruchart C, Morschhauser F, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35(22):2473–81. https://doi.org/10.1200/JCO.2017.72.6984.CrossRefPubMed

36.

Vitolo U, Witzig TE, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: first report of phase III randomized study of lenalidomide/R-CHOP (R2-CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematol Oncol. 2019;37(S2):36–7. https://doi.org/10.1002/hon.5_2629.CrossRef

37.

Oberic L, Puyade M, Peyrade F, Maisonneuve H, Abraham J, Feugier P, et al. Sub-cutaneous rituximab-minichop versus sub-cutaneous rituximab-minichop + lenalidomide (R2-miniCHOP) in diffuse large B cell lymphoma for patients of 80 years old or more (SENIOR study): a multicentric randomized phase III study of the Lysa. Blood. 2019;134(Supplement_1):352. https://doi.org/10.1182/blood-2019-123612.CrossRef

38.

Nowakowski GS, Hong F, Scott DW, Macon R, King RL, Habermann TM, et al. Addition of lenalidomide to R-chop (R2CHOP) improves outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL): first report of ECOG-acrin1412 a randomized phase 2 us intergroup study of R2CHOP vs R-CHOP. Hematol Oncol. 2019;37(S2):37–8. https://doi.org/10.1002/hon.6_2629.CrossRef

39.

Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117(22):5058–66. https://doi.org/10.1002/cncr.26135.CrossRefPubMed

40.

Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol. 2014;166(1):77–83. https://doi.org/10.1111/bjh.12846.CrossRefPubMedPubMedCentral

41.

Martin A, Redondo AM, Dlouhy I, Salar A, Gonzalez-Barca E, Canales M, et al. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. Br J Haematol. 2016;173(2):245–52. https://doi.org/10.1111/bjh.13945.CrossRefPubMed

42.

Zinzani PL, Pellegrini C, Argnani L, Broccoli A. Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab. Haematologica. 2016;101(9):e385–6. https://doi.org/10.3324/haematol.2016.147256.CrossRefPubMedPubMedCentral

43.

Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Molucon-Chabrot C, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective “proof of concept” phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)dagger. Ann Oncol. 2019;30(4):621–8. https://doi.org/10.1093/annonc/mdz032.CrossRefPubMed

44.

Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018;2(13):1595–607. https://doi.org/10.1182/bloodadvances.2017014845.CrossRefPubMedPubMedCentral

45.

Hai-bing Y, Ya-xun W, Nan-nan C, Jie-yu H, Jia-tai W, Kui D, et al. Expression of PD-1 and PD-L1 in diffuse large B-cell lymphoma. Chin J Clin Exp Pathol. 2019;35(4):379–82.

46.

Sheikh S, Kuruvilla J. Pembrolizumab for the treatment of diffuse large B-cell lymphoma. Expert Opin Biol Therapy. 2019;19(11):1119–26. https://doi.org/10.1080/14712598.2019.1659777.CrossRef

47.

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155. https://doi.org/10.1186/s12943-019-1091-2.CrossRefPubMedPubMedCentral

48.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704. https://doi.org/10.1200/JCO.2015.65.9789.CrossRefPubMedPubMedCentral

49.

Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, et al. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020;4(1):122–6. https://doi.org/10.1182/bloodadvances.2019000784.CrossRefPubMedPubMedCentral

50.

Smith SD, Till BG, Shadman MS, Lynch RC, Cowan AJ, Wu QV, et al. Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy. Br J Haematol. 2020;189(6):1119–26. https://doi.org/10.1111/bjh.16494.CrossRefPubMed

51.

Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699–713. https://doi.org/10.1016/j.cell.2010.07.044.CrossRefPubMedPubMedCentral

52.

Advani R, Bartlett NL, Smith SM, Roschewski M, Popplewell L, Flinn I, et al. The first-in-class anti-Cd47 antibody Hu5f9-G4 + rituximab induces durable responses in relapsed/refractory Dlbcl and indolent lymphoma: interim phase 1b/2 results. Hematol Oncol. 2019;37(S2):89–90. https://doi.org/10.1002/hon.57_2629.CrossRef

53.

Liu B, Guo H, Xu J, Qin T, Guo Q, Gu N, et al. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses. MAbs. 2018;10(2):315–24. https://doi.org/10.1080/19420862.2017.1409319.CrossRefPubMed

54.

Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529–37. https://doi.org/10.1200/JCO.2017.73.3402.CrossRefPubMed

55.

Peyrade F, Bologna S, Delwail V, Emile JF, Pascal L, Fermé C, et al. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group. Lancet Haematol. 2017;4(1):e46–55. https://doi.org/10.1016/S2352-3026(16)30171-5.CrossRefPubMed

56.

Flinn IW, Erter J, Daniel DB, Mace JR, Berdeja JG. Phase II study of bendamustine and ofatumumab in elderly patients with newly diagnosed diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy. Oncologist. 2019;24(8):1035-e623. https://doi.org/10.1634/theoncologist.2019-0286.CrossRefPubMedPubMedCentral

57.

Fanale MA, Hamlin PA, Park SI, Persky DO, Higgins JP, Burnett C, et al. Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study. J Clin Oncol. 2018;36(15_suppl):7580. https://doi.org/10.1200/JCO.2018.36.15_suppl.7580.CrossRef

58.

Persky DO, Musteata V, Zodelava M, Perekhrestenko T, Diaz AE, Guthrie TH, et al. A phase 2 study of MT-3724 to evaluate safety, pharmacodynamics and efficacy of MT-3724 for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 2019;134(Supplement_1):5324. https://doi.org/10.1182/blood-2019-128604.CrossRef

59.

Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, et al. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015;125(2):236–41. https://doi.org/10.1182/blood-2014-06-584623.CrossRefPubMedPubMedCentral

60.

Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ, et al. PET-directed therapy for patients with limited-stage diffuse large B-cell lymphoma—results of intergroup Nctn study S1001. Blood. 2019;134(Supplement_1):349. https://doi.org/10.1182/blood-2019-123871.CrossRef

61.

Friedberg JW, Unger JM, Burack WR, Gopal AK, Raju RN, Nademanee AP, et al. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol. 2014;166(3):382–9. https://doi.org/10.1111/bjh.12906.CrossRefPubMedPubMedCentral

62.

Morin RD, Assouline S, Alcaide M, Mohajeri A, Johnston RL, Chong L, et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res. 2016;22(9):2290–300. https://doi.org/10.1158/1078-0432.CCR-15-2123.CrossRefPubMed

63.

Sehn LH, Matasar MJ, Flowers CR, Kamdar M, McMillan AK, Hertzberg M, et al. Polatuzumab vedotin plus bendamustine with rituximab in relapsed/refractory diffuse large B-cell lymphoma: updated results of a phase Ib/II randomized study. Blood. 2019;134(Supplement_1):4081. https://doi.org/10.1182/blood-2019-123449.CrossRef

64.

Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study. Lancet Oncol. 2019;20(7):998–1010. https://doi.org/10.1016/S1470-2045(19)30091-9.CrossRefPubMed

65.

Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6(5):e254–65. https://doi.org/10.1016/S2352-3026(19)30026-2.CrossRefPubMed

66.

Tilly H, Flowers C, Friedberg JW, Herbaux C, Morschhauser F, Sehn LH, et al. POLARIX: a phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL. J Clin Oncol. 2019;37(15 suppl):TPS7571-TPS. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS7571.CrossRef

67.

McMillan AK, Matasar MJ, Sancho J-M, Viardot A, Hernandez J, Perretti T, et al. POLARGO: a randomized phase III study evaluating polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma who had received one or more previous therapies. Blood. 2019;134(Supplement_1):5317. https://doi.org/10.1182/blood-2019-123673.CrossRef

68.

Jurczak W, Zinzani PL, Hess G, Gaidano G, Provencio M, Nagy Z, et al. A phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma: long-term follow-up, final analysis. Blood. 2019;134(Supplement 1):4078. https://doi.org/10.1182/blood-2019-124297.CrossRef

69.

Düll J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, de Vos S, et al., editors. Subgroup analyses from L-MIND, a Phase II study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. ASH Annual Meeting and; 2019 December 7, 2019. Orlando, Florida: American Society of Hematology.

70.

Ohmachi K, Ogura M, Suehiro Y, Ando K, Uchida T, Choi I, et al. A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. Int J Hematol. 2019;109(6):657–64. https://doi.org/10.1007/s12185-019-02635-9.CrossRefPubMed

71.

Trnĕný M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, et al. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018;103(8):1351–8. https://doi.org/10.3324/haematol.2017.168401.CrossRefPubMedPubMedCentral

72.

Kahl BS, Hamadani M, Radford J, Carlo-Stella C, Caimi P, Reid E, et al. A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed/refractory B-cell non-hodgkin lymphoma. Clin Cancer Res. 2019;25(23):6986–94. https://doi.org/10.1158/1078-0432.CCR-19-0711.CrossRefPubMed

73.

Leonard JP. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin’s lymphoma: phase I/II clinical trial results. Clin Cancer Res. 2004;10(16):5327–34. https://doi.org/10.1158/1078-0432.CCR-04-0294.CrossRefPubMed

74.

Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(22):5044–51. https://doi.org/10.1200/JCO.2005.13.821.CrossRefPubMed

75.

Micallef INM, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15):4053–61. https://doi.org/10.1182/blood-2011-02-336990.CrossRefPubMedPubMedCentral

76.

Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–83. https://doi.org/10.1200/JCO.2012.42.7211.CrossRefPubMedPubMedCentral

77.

Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2018;182(4):583–6. https://doi.org/10.1111/bjh.14820.CrossRefPubMed

78.

Kim SJ, Yoon DH, Kim JS, Kang HJ, Lee HW, Eom H-S, et al. Efficacy of brentuximab vedotin in relapsed or refractory high-CD30-expressing non-hodgkin lymphomas: results of a multicenter, open-labeled phase II trial. Cancer Res Treat. 2019;52(2):374–87.CrossRef

79.

Hu S, Xu-Monette ZY, Balasubramanyam A, Manyam GC, Visco C, Tzankov A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715–24. https://doi.org/10.1182/blood-2012-10-461848.CrossRefPubMedPubMedCentral

80.

Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–402. https://doi.org/10.1182/blood-2014-09-598763.CrossRefPubMed

81.

Bartlett NL, Smith MR, Siddiqi T, Advani RH, O’Connor OA, Sharman JP, et al. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leukemia Lymphoma. 2017;58(7):1607–16. https://doi.org/10.1080/10428194.2016.1256481.CrossRefPubMed

82.

Zhao S, Molina A, Yu A, Hanson J, Cheung H, Li X, et al. High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti-CD74-drug conjugate. J Pathol Clin Res. 2019;5(1):12–24. https://doi.org/10.1002/cjp2.114.CrossRefPubMed

83.

Shah NN, Krishnan AY, Shah ND, Burke JM, Melear JM, Spira AI, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies. Blood. 2019;134(Supplement_1):5329. https://doi.org/10.1182/blood-2019-122754.CrossRef

84.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.CrossRef

85.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–407. https://doi.org/10.1056/NEJMoa1801445.CrossRefPubMedPubMedCentral

86.

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–90. https://doi.org/10.1038/s41591-018-0016-8.CrossRefPubMedPubMedCentral

87.

Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37(4):551-68.e14. https://doi.org/10.1016/j.ccell.2020.03.015.CrossRefPubMed

88.

Wang W-G, Cui W-L, Wang L, Zhu F, Wan X-C, Ping B, et al. Loss of B-cell receptor expression defines a subset of diffuse large b-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features. Am J Surg Pathol. 2015;39(7):902–11.CrossRef

89.

Flinn IW, Bartlett NL, Blum KA, Ardeshna KM, LaCasce AS, Flowers CR, et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Eur J Cancer. 2016;54:11–7.CrossRef

90.

Burke JM, Shustov A, Essell J, Patel-Donnelly D, Yang J, Chen R, et al. An open-label, phase II trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leukemia. 2018;18(8):e327–31. https://doi.org/10.1016/j.clml.2018.05.022.CrossRef

91.

Nagel D, Bognar M, Eitelhuber AC, Kutzner K, Vincendeau M, Krappmann D. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma. Oncotarget. 2015;6(39):42232–42. https://doi.org/10.18632/oncotarget.6273.CrossRefPubMedPubMedCentral

92.

Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–6. https://doi.org/10.1038/nm.3884.CrossRefPubMed

93.

Sauter CS, Matasar MJ, Schoder H, Devlin SM, Drullinsky P, Gerecitano J, et al. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood. 2018;131(16):1805–8. https://doi.org/10.1182/blood-2017-08-802561.CrossRefPubMedPubMedCentral

94.

Zhang SQ, Smith SM, Zhang SY, Lynn WY. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2015;170(4):445–56. https://doi.org/10.1111/bjh.13427.CrossRefPubMed

95.

Batlevi CL, De Frank S, Stewart C, Hamlin PA, Matasar MJ, Gerecitano JF, et al. Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. J Clin Oncol. 2018;36(15_suppl):7520. https://doi.org/10.1200/JCO.2018.36.15_suppl.7520.CrossRef

96.

Dyer MJ, De Vos S, Ruan J, Flowers C, Maddocks KJ, Rule S, et al. Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2018;36(15_suppl):7547.CrossRef

97.

Witzig TE, Maddocks KJ, De Vos S, Lyons RM, Edenfield WJ, Sharman JP, et al. Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2019;37(15_suppl):7519. https://doi.org/10.1200/JCO.2019.37.15_suppl.7519.CrossRef

98.

Hainsworth JD, Arrowsmith ER, McCleod M, Hsi ED, Hamid O, Shi P, et al. A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma. Leukemia Lymphoma. 2016;57(1):216–8. https://doi.org/10.3109/10428194.2015.1045898.CrossRefPubMed

99.

Zhu J, Nowakowski G, Zhang Q, Brody J, Sun X, Maly J, et al. Engine: phase III randomized study of enzastaurin/R-CHOP versus Placebo/R-CHOP in frontline high risk diffuse large B cell lymphoma patients with novel genomic biomarker DGM1. Blood. 2019;134(Supplement_1):5330. https://doi.org/10.1182/blood-2019-124930.CrossRef

100.

Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440.CrossRef

101.

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33. https://doi.org/10.1200/JCO.2016.70.4320.CrossRefPubMedPubMedCentral

102.

Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019;133(18):1964–76. https://doi.org/10.1182/blood-2018-11-880526.CrossRefPubMedPubMedCentral

103.

Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Gerson JN, et al. Treatment of patients with relapsed/refractory non-hodgkin lymphoma with venetoclax: a single-center evaluation of off-label use. Clin Lymphoma Myeloma Leukemia. 2019;19(12):791–8. https://doi.org/10.1016/j.clml.2019.09.612.CrossRef

104.

Ackler S, Mitten M, Chen J, Clarin J, Foster K, Jin S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin’s lymphoma tumours in vivo. Br J Pharmacol. 2012;167(4):881–91. https://doi.org/10.1111/j.1476-5381.2012.02048.x.CrossRefPubMedPubMedCentral

105.

Seymour JF, Pfreundschuh M, Trnĕný M, Sehn LH, Catalano J, Csinady E, et al. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica. 2014;99(8):1343–9. https://doi.org/10.3324/haematol.2013.100818.CrossRefPubMedPubMedCentral

106.

Ma X, Li L, Zhang L, Fu X, Li X, Wang X, et al. Apatinib in patients with relapsed or refractory diffuse large B cell lymphoma: a phase II, open-label, single-arm, prospective study. Drug Des Dev Therapy. 2020;14:275–84. https://doi.org/10.2147/DDDT.S227477.CrossRef

107.

Yin H, Zhong F, Ouyang Y, Wang Q, Ding L, He S. Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in non-Hodgkin’s lymphoma. Hematology (Amsterdam, Netherlands). 2017;22(9):527–35. https://doi.org/10.1080/10245332.2017.1312205.CrossRef

108.

Lenz G, Hawkes E, Verhoef G, Haioun C, Lim ST, Heo DS, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;38:1–14.

109.

Coleman M, Belada D, Casasnovas R-O, Gressin R, Lee H-P, Mehta A, et al. Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202). J Clin Oncol. 2019;37(15_suppl):e19038-e. https://doi.org/10.1200/JCO.2019.37.15_suppl.e19038.CrossRef

110.

Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25(2):341–7. https://doi.org/10.1038/leu.2010.226.CrossRefPubMed

111.

Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol. 2010;28(31):4740–6. https://doi.org/10.1200/JCO.2010.29.2813.CrossRefPubMedPubMedCentral

112.

Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica. 2013;98(4):615–9. https://doi.org/10.3324/haematol.2012.075184.CrossRefPubMedPubMedCentral

113.

Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, et al. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2018;29(3):707–14. https://doi.org/10.1093/annonc/mdx764.CrossRefPubMed

114.

Witzig TE, LaPlant B, Habermann TM, McPhail E, Inwards DJ, Micallef IN, et al. High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance). Blood Cancer J. 2017;7(6):e576-e. https://doi.org/10.1038/bcj.2017.57.CrossRef

115.

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88–92. https://doi.org/10.1038/nature08638.CrossRefPubMedPubMedCentral

116.

Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069–76. https://doi.org/10.1182/blood-2009-01-199679.CrossRefPubMedPubMedCentral

117.

Desai S, Maurin M, Smith MA, Bolick SC, Dessureault S, Tao J, et al. PRDM1 is required for mantle cell lymphoma response to bortezomib. Mol Cancer Res. 2010;8(6):907–18. https://doi.org/10.1158/1541-7786.MCR-10-0131.CrossRefPubMedPubMedCentral

118.

Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, et al. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 2017;31(3):625–36. https://doi.org/10.1038/leu.2016.243.CrossRefPubMed

119.

Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood. 2019;134(13):1024–36. https://doi.org/10.1182/blood.2018891598.CrossRefPubMedPubMedCentral

120.

Westin JR, Nastoupil LJ, Fayad L, Hagemeister FB, Oki Y, Turturro F, et al. Smart start: rituximab, lenalidomide, and ibrutinib alone and in combination with standard chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma: final phase II results. Blood. 2019;134(Supplement_1):1581. https://doi.org/10.1182/blood-2019-128475.CrossRef

121.

Huang X, Meng B, Iqbal J, Ding BB, Perry AM, Cao W, et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2013;31(36):4520–8. https://doi.org/10.1200/JCO.2012.45.6004.CrossRefPubMedPubMedCentral

122.

Forero-Torres A, Ramchandren R, Yacoub A, Wertheim M, Edenfield W, Caimi P, et al. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133:blood:2018. https://doi.org/10.1182/blood-2018-08-867499.CrossRef

123.

Kallam A, Witzig TE, Roschewski MJ, Lyden E, Lunning MA, Bierman PJ, et al. Phase II multi-center study of ruxolitinib phosphate for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL). J Clin Oncol. 2019;37(15):e19063-e. https://doi.org/10.1200/JCO.2019.37.15_suppl.e19063.CrossRef

124.

Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018;6(1):119. https://doi.org/10.1186/s40425-018-0436-5.CrossRefPubMedPubMedCentral

125.

Ben-Barouch S, Kuruvilla J. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL). Expert Opin Investig Drugs. 2020;29(1):15–21. https://doi.org/10.1080/13543784.2020.1706087.CrossRefPubMed

126.

Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511–22. https://doi.org/10.1016/S2352-3026(20)30120-4.CrossRefPubMed

127.

Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185–94. https://doi.org/10.1182/blood-2016-02-699520.CrossRefPubMedPubMedCentral

128.

Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, et al. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations. JCI Insight. 2018;2(6):1–14. https://doi.org/10.1172/jci.insight.90196.CrossRef

129.

Herrera AF, Chen L, Popplewell LL, Budde LE, Mei M, Armenian SH, et al. Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large b-cell lymphoma, follicular lymphoma, and hodgkin lymphoma. Blood. 2019;134(Supplement_1):759. https://doi.org/10.1182/blood-2019-123163.CrossRef

130.

Italiano A, Soria J-C, Toulmonde M, Michot J-M, Lucchesi C, Varga A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649–59. https://doi.org/10.1016/S1470-2045(18)30145-1.CrossRefPubMed

131.

Morschhauser F, Salles G, McKay P, Tilly H, Schmitt A, Gerecitano J, et al. Interim report from a phase 2 multicenter study of Tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Hematol Oncol. 2017;35(S2):24–5. https://doi.org/10.1002/hon.2437_3.CrossRef

132.

Sarkozy C, Morschhauser F, Dubois S, Molina T, Michot J-M, Cuillière-Dartigues P, et al. A LYSA Phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in newly diagnosed diffuse large B cell lymphoma (DLBCL) patients with poor prognosis features. Clin Cancer Res. 2020. https://doi.org/10.1158/1078-0432.CCR-19-3741.CrossRefPubMed

133.

Bordon Y. Mucosal immunology: microbiota-induced T cells block allergic inflammation. Nat Rev Immunol. 2015;15(8):468. https://doi.org/10.1038/nri3894.CrossRefPubMed

134.

Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20(2):216–28. https://doi.org/10.1016/S1470-2045(18)30747-2.CrossRefPubMed

135.

Hama Y, Banjo T, Honma D, Takata Y, Nosaka E, Shiroishi M, et al. Anti-tumor effect of the EZH1/2 dual inhibitor valemetostat against diffuse large B-cell lymphoma via modulation of b-cell receptor signaling and c-Myc signaling pathways. Blood. 2019;134(Supplement_1):4642. https://doi.org/10.1182/blood-2019-125436.CrossRef

136.

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–17. https://doi.org/10.1016/j.cell.2011.08.017.CrossRefPubMedPubMedCentral

137.

Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. 2015;21(7):1628–38. https://doi.org/10.1158/1078-0432.CCR-14-1561.CrossRefPubMed

138.

Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knutson D, et al. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12(1):73. https://doi.org/10.1186/s13045-019-0761-2.CrossRefPubMedPubMedCentral

139.

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang ML, Arnason JE, et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood. 2019;134(Supplement_1):241. https://doi.org/10.1182/blood-2019-127508.CrossRef

140.

He P, Liu H, Liu H, Luo M, Feng H, Li Q, et al. First-in-human study of ET019003, a next generation anti-CD19 T-cell therapy, in patients with relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL). Blood. 2019;134(Supplement_1):2870. https://doi.org/10.1182/blood-2019-131414.CrossRef

141.

Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Therapy J Am Soc Gene Therapy. 2017;25(10):2245–53. https://doi.org/10.1016/j.ymthe.2017.07.004.CrossRef

142.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, et al. Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematol. 2017;4(1):e35–45. https://doi.org/10.1016/S2352-3026(16)30168-5.CrossRefPubMed

143.

Cavallo F, Follows GA, Goy A, Vermaat J, Casasnovas R-O, Lavee O, et al. Effect of prior therapy on the efficacy and safety of oral selinexor in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): a post-hoc analysis of the sadal study. Blood. 2019;134(Supplement_1):5333. https://doi.org/10.1182/blood-2019-122900.CrossRef

144.

Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, et al. NCCN guidelines insights: B-cell lymphomas, version 3.2019. J Natl Compr Canc Netw. 2019;17(6):650–61. https://doi.org/10.6004/jnccn.2019.0029.CrossRefPubMed

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

New agents and regimens for diffuse large B cell lymphoma

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy

Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition

Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer